Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Will COVID-19 vaccines be updated by fall? 

By Brian Buntz | June 27, 2022

vaccine

Photo by Frank Meriño from Pexels

FDA advisors are slated to meet to discuss the prospect of updating the first generation of COVID-19 vaccines for use as boosters this fall and winter.

But it remains unclear whether updating the COVID-19 vaccines will be necessary. Both Pfizer (NYSE:PFE) and Moderna (Nasdaq:MRNA) have updated vaccines in the works.

Pfizer and Moderna have both said their next-generation vaccines appear to be more effective against the omicron BA.1 variant. But fighting the growing number of omicron lineages could prove challenging. For example, the recent emergence of BA.4 and BA.5 subvariants threatens those infected with older omicron variants.

Pfizer noted in a press release that it was developing monovalent and bivalent versions of its COVID-19 vaccine, developed jointly with BioNTech. Protection appeared to be substantially stronger against the BA.1 subvariant than the BA.4/BA.5 subvariants. Still, the companies plan on gathering additional data on vaccine performance relative to the BA.4/BA.5 variants in the coming weeks.

GSK plc (LSE/NYSE:GSK) and Sanofi (NYSE:GSK) have also announced that their adjuvanted bivalent vaccine candidate was efficacious against omicron in adults in stage 2 of a Phase 3 study. That vaccine candidate is based on the original D614 virus and the beta (B.1.351) strain.

BA.4 and BA.5 currently are responsible for more than one-third of COVID-19 infections in the U.S.

Other variants are likely to emerge between now and the fall.

But current COVID-19 vaccines are less effective at generating neutralizing antibodies against BA.4 and BA.5 than the first version of omicron.

Assuming SARS-CoV-2 doesn’t evolve significantly between now and fall, updated vaccine versions are “more likely to be helpful” than readministering the existing vaccines, Dr. William Hanage of the Harvard T.H. Chan School of Public Health told ABC News.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Pfizer logo
Pfizer CEO tests positive for COVID-19
Pfizer logo
Pfizer and BioNTech seek EMA authorization for COVID-19 vaccination in young children
Pfizer logo
FDA allows pharmacists to prescribe Paxlovid 
COVID-19 vaccine
Young children in U.S. now eligible for COVID-19 vaccination

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards